Madrigal Pharmaceuticals, Inc. (MDGL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / November 11, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Madrigal Pharmaceuticals, Inc. ("Madrigal" or "the Company") (NASDAQ:MDGL). Investors who purchased Madrigal securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/madrigal-pharmaceuticals-inc-mdgl-investigation.

Madrigal Investigation Details

On November 3, 2026, Madrigal disclosed in its quarterly report that its former Senior Vice President and Head of Clinical Development, Dr. Michael Charlton, had filed a whistleblower complaint against the Company. According to the complaint, Dr. Charlton repeatedly reported concerns that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with source data, and allowing an unblinded board member and major shareholder to control the adjudication of clinical outcomes. Following this news, Madrigal's stock price dropped.

What's Next for Madrigal Investors?

If you are aware of any facts relating to this investigation or purchased Madrigal securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/madrigal-pharmaceuticals-inc-mdgl-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Madrigal Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Madrigal Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk